Table: q1_q4_2022_prescription_drugs_intro_to_market , manufacturer_name like U*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
United Therapeutics	66302063203	Tyvaso DPI Maintenance Kit Inhalation Powder 112 cartridges of 32 MCG with 5 inhalers per box	2022-06-22	20906.0900	United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply). Tyvaso DPI is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment.	None	75000	None	None	None	None	None	None	Estimated patients is confidential and proprietary, and not publicly available or within the public domain.	None
United Therapeutics	66302064803	Tyvaso DPI Maintenance Kit Inhalation Powder 112 cartridges of 48 MCG with 5 inhalers per box	2022-06-22	20906.0900	United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply). Tyvaso DPI is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment.	None	75000	None	None	None	None	None	None	Estimated patients is confidential and proprietary, and not publicly available or within the public domain.	None
United Therapeutics	66302066403	Tyvaso DPI Maintenance Kit Inhalation Powder 112 cartridges of 64 MCG with 5 inhalers per box	2022-06-22	20906.0900	United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply). Tyvaso DPI is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment.	None	75000	None	None	None	None	None	None	Estimated patients is confidential and proprietary, and not publicly available or within the public domain.	None
United Therapeutics	66302060002	TYVASO DPI Titration Kit Inhalation Powder 112 cartridges of 16 MCG and 84 cartridges of 32 MCG with 5 inhalers per box	2022-07-27	20906.0900	"United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply). Tyvaso DPI is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment."	None	75000	None	1	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=664
United Therapeutics	66302061603	Tyvaso DPI Maintenance Kit Inhalation Powder 112 cartridges of 16 MCG with 5 inhalers per box	2022-08-02	20906.0900	United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply). Tyvaso DPI is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment.	None	75000	None	1	None	None	None	None	None	None
United Therapeutics	66302061002	Tyvaso DPI Titration Kit Inhalation Powder 112 cartridges of 16 MCG and 112 cartridges of 32 MCG and 28 cartridges of 48 MCG with 5 inhalers per box	2022-08-04	20906.0900	United Therapeutics considers multiple factors when setting a list price for a medicine, including: benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. Market and business considerations, including: Ongoing research-investment costs, Medical- and patient-service costs (which may or may not include patient assistance programs and capital-investment costs associated with manufacturing, storage and supply). Tyvaso DPI is an FDA approved treatment which affects a number of patients in the US annually. United Therapeutic's approach will focus on educating healthcare providers on how to identify and diagnose potential patients to provide relief from symptoms as early as possible - the education will provide information about treatment.	None	75000	None	1	None	None	None	None	None	None
USWM, LLC	78670014002	ZIMHI Injection 5 mg/.5mL	2022-03-31	125.0000	To help reduce the number of deaths resulting from the opioid crisis by increasing access to higher dose naloxone. This will be achieved by educating public health entities (including State supported naloxone distribution programs, Harm Reduction, Law Enforcement and Emergency First Responders, Community Support programs) and all other channels including specialty distributors, specialty pharmacies, advocacy groups, physicians, patients, and health systems on the approved indication, efficacy, safety, and administration of the pre-filled naloxone device. ZIMHI will utilize a multitude of marketing resources including a Public Health & Advocacy relations team for the US, a small field sales force to educate HCP’s, digital education and ordering, a website, medical conferences, advocacy meetings, etc. to compliantly engage the aforementioned interest groups.	None	10000000	None	1	None	None	None	None	USWM, LLC has a distribution and commercialization agreement with Adamis Pharmaceuticals Corp to distribute this product. USWM purchases the finished product from Adamis through terms specified in a supply agreement.	None